At the end of last year, the Moscow Endocrine Plant launched production of COVID-19 medications. At present, the company specializes in the production of anticoagulants. They prevent the formation of blood clots in blood vessels, which are one of the harshest complications after a person suffers from coronavirus. The plant produces calcium nadroparin, heparin and sodium enoxaparin. In addition, the company manufactures interferon-based antiviral drugs, the famous Remantadine and liquid for hypodermic injections.

Endocrine Plant is one of the largest and most powerful pharmaceutical manufacturers in Moscow. Before the pandemic, it specialized mainly in medications for pain relief. However, due to the coronavirus situation, the organization quickly reoriented its activities and started producing medicines that were completely atypical for it.

Alexander Prokhorov, head of the capital's Department of Investment and Industry, noted that there are currently more than 25 companies in the city for the manufacture of various medicines. Several more productions are under construction and launch. However, it is thanks to the extensive production capacity of the Moscow Endocrine Plant, which has increased the production of heparin group medicines several times, the residents of the capital will definitely have no shortage of them.

Last year the endocrine plant underwent modernization and was equipped with additional high-tech equipment. It was equipped with lines that allow the production of new dosage forms of Midazolam and Sibazone. These medications are used to treat children suffering from seizures (generalized tonic, clonic, and tonic-clonic). Previously, drugs of such action were not produced in our country, so they were purchased through imports.

Moscow Health Department has signed contracts with the giant plant for the supply of medicines under 12 international nonproprietary names (INN). The total sum of the deals is an impressive 106 million rubles. Thanks to this, over 25 thousand needy Muscovites (including beneficiaries, patients of hospitals and municipal polyclinics) received the necessary medicines in time.

As of today, 124 medical institutions purchase medicines produced by the Moscow Endocrine Plant. About 90% of the drugs that the city buys from the company are centrally acting analgesics (including 7 INNs, which only this plant produces in our country). For 11 months of 2020, 5,690 inpatients received analgesics from the Moscow Endocrine Plant.

Mikhail Fonarev, General Director of the plant, noted that the enterprise, among other things, produces calcium nadroparin, which is completely in line with foreign analogues. According to Sergey Tsyb, the First Deputy Minister of Industry and Trade of the Russian Federation, the registration certificate for this drug was issued last December. And in 2021 it is planned to obtain approvals for enoxaparin sodium, which will also be produced by the Moscow Endocrine Plant. The official said that the total planned production volume of heparin series drugs will be about 30 million pre-filled syringes per year. If this figure is achieved, it will not only fully meet the needs of Moscow residents, but also to establish the supply of medicines in other regions of the Russian Federation.

A few facts from the history of the Moscow Endocrine Plant

The facility was founded in May 1943 on the basis of a meat processing plant, named after a prominent political figure of the USSR - A.I. Mikoyan. During the Great Patriotic War the plant supplied to the front and the home front vital medicines: insulin, miol, thyreoidin.

In the 1960s the plant started production of "Pantocrine", which was called the elixir of long life and good health. The drug was made from maral antlers, which is why the emblem of the Moscow endocrine plant has a silhouette of a deer, which is its hallmark to this day.

After the collapse of the Soviet Union, in the years of perestroika, our country ceased to receive raw materials for drugs from the republics, which are now autonomous. Therefore, the endocrine plant has relied on its own production facilities, increasing the volume and range of production of analgesics and other medicines.

Today the Moscow Endocrine Plant can be called the face of the pharmaceutical industry of the Russian Federation. This is the largest enterprise of this sphere in the capital in terms of staff. The company's head office is located on Novokhokhlovskaya Street, 5 (Moscow). The plant has two branches:

• In the Bryansk region (Ramasukhskoye urban settlement). The subsidiary is called Pochep;

• in Moscow (Entuziastov Highway). This branch is called Lefortovsky.

In addition to manufacturing analgesics - its main specialty - the Moscow Endocrine Plant produces drugs used in the following branches of medicine:

• gynecology;
• anesthesiology;
• cardiology;
• psychoneurology;
• ophthalmology.

But this is not yet a complete list of the capital's pharmaceutical giant's products. The Moscow endocrine plant also produces anti-inflammatory drugs and metabolics:

• Taufon eye drops;
• Remantadin antiviral drug;
• Naphtisin nasal drops;
• nootropic "Phenibut", etc.

More than half of the products the company supplies to the market are included in the list of vitally important medicines. And the Moscow Endocrine Plant is also the only enterprise in our country, which produces analgesics of central action. They are used to help people with cancer.

The company has an impressive production capacity, which allows to produce medicines in a variety of forms and aggregate states: in syringes, as a liquid or suspension, in the form of patches, ointments, pills, etc. In 2018, the plant managed to increase the market share of Russian narcotic drugs and psychotropics more than 2 times - from 42 to 98%.